NEOG vs VREX vs BFLY Stock Comparison

Neogen, Varex Imaging and Butterfly Network Prices as of Oct 29, 2026 Peers: Industry group
1 more company in this comparison (LNTH) Create a free account to keep reading and compare up to 10 companies.
NEOG Neogen Corp
$12.26 -3.7% 1M +96.8% 1Y
Market cap
$2.56B
P/E
–
Revenue (TTM)
$883.99M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins
VREX Varex Imaging Corp
$18.44 -0.2% 1M +53.4% 1Y
Market cap
$775.90M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare
4 wins
BFLY Butterfly Network, Inc.
$7.51 -17.5% 1M +249.3% 1Y
Market cap
$1.67B
P/E
–
Revenue (TTM)
$123.25M
Div. yield
–
Diagnostic Equipment Healthcare
3 wins

Head to Head

10 decided of 12

Varex Imaging leads on 4 of the 12 questions below (Varex Imaging 4, Neogen 3, Butterfly Network 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionNEOGVREXBFLYLeader
Larger companyMarket capitalisation $2.56B $775.90M $1.67B NEOG
Cheaper on earningsLower P/E, profitable companies only -45.6x 35.1x -31.1x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 38.3x 21.2x — VREX
Faster revenue growthRevenue growth, trailing twelve months -0.3% +5.3% +39.4% BFLY
More profitableNet margin, trailing twelve months -6.3% 2.6% — VREX
Better return on capitalReturn on invested capital -0.2% 6.9% — VREX
Less leveragedLower net debt / EBITDA 5.4x 2.5x — VREX
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +96.8% +53.4% +249.3% BFLY
Better 5-year returnAnnualised price return, 5 years -22.0%/yr -7.2%/yr -6.2%/yr BFLY
Less volatileAnnualised volatility, 1 year 55.7% 57.2% 115.0% NEOG
Higher overall scoreMean of the five percentile scores vs peers 57/100 51/100 47/100 NEOG

Percentile Scorecard

NEOGVREXBFLY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisNEOGVREXBFLY
Valuation 73 #62 of 227 85 #34 of 227 21 #179 of 227
Growth 49 #111 of 218 24 #166 of 218 90 #23 of 218
Profitability 63 #76 of 202 67 #67 of 202 29 #144 of 202
Financial Health 47 #125 of 233 43 #133 of 233 –
Shareholder Returns 55 #59 of 130 35 #85 of 130 –
Overall 57 51 47
  • NEOG ranked among 247 companies in Medical Devices and Diagnostics
  • VREX ranked among 247 companies in Medical Devices and Diagnostics
  • BFLY ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodNEOGVREXBFLYSPY
1 month -3.7%-0.2%-17.5% +0.7%
3 months +6.3%+66.6%-8.0% +3.7%
6 months +30.4%+58.3%+56.8% +7.1%
Year to date +75.4%+58.3%+97.6% +12.8%
1 year +96.8%+53.4%+249.3% +11.9%
3 years -18.6%+3.0%+827.2% +85.2%
3 years, per year -6.6%+1.0%+110.2% +22.8%
5 years -71.0%-31.3%-27.2% +67.6%
5 years, per year -22.0%-7.2%-6.2% +10.9%
10 years -37.3%—— +262.0%
10 years, per year -4.6%—— +13.7%

Risk

MeasureNEOGVREXBFLYSPY
Volatility, 1Y 55.7%57.2%115.0% 12.7%
Downside volatility, 1Y 46.7%49.5%91.8% 12.6%
Beta vs S&P 500, 1Y 1.441.103.02 1.00
Return / volatility, 1Y 1.740.932.17 0.94
Max drawdown, 5Y -90.6%-78.8%-93.4% -25.4%
From 52-week high -12.3%-0.8%-24.4% -1.2%
52-week high $13.98$18.58$9.94 $779.14
52-week low $5.41$9.32$1.97 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleNEOGVREXBFLY
P/E now vs peer median -47.7xmedian 28.7x 35.1xmedian 28.7x -36.7xmedian 28.7x
P/S now vs peer median 3.0xmedian 3.0x 0.9xmedian 3.0x 14.5xmedian 3.0x
EV/EBITDA now vs peer median 29.6xmedian 17.8x 10.1xmedian 17.8x —median 17.8x
P/FCF now vs peer median 53.7xmedian 26.4x -38.5xmedian 26.4x -77.2xmedian 26.4x
P/B now vs peer median 1.3xmedian 2.4x 1.5xmedian 2.4x 9.7xmedian 2.4x
PEG now vs peer median 1.70median 0.99 -9.16median 0.99 -1.22median 0.99

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsNEOGVREXBFLY
Revenue $883.99M $865.00M $123.25M
Gross profit $418.98M $296.90M $86.60M
Operating income -$7.38M $72.20M -$57.83M
Net income -$56.10M $22.40M -$53.69M
Free cash flow $49.80M -$20.20M –
R&D $19.76M $91.40M $39.57M
EPS (diluted) $-0.26 $0.52 $-0.20
Cash & equivalents $172.00M $99.20M $122.30M
Total debt $774.20M $347.10M –
Shares (diluted) 218.10M 42.60M 262.10M
Enterprise value $1.89B $307.70M $1.67B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricNEOGVREXBFLY
P/E -47.7x 35.1x -36.7x
P/FCF 53.7x -38.5x -77.2x
P/Operating cash flow 31.4x 68.8x -76.4x
P/S 3.0x 0.9x 14.5x
P/B 1.3x 1.5x 9.7x
P/Tangible book 3.4x 1.6x 10.0x
EV/EBITDA 29.6x 10.1x –
EV/EBIT -444.4x 14.2x –
EV/Revenue 3.7x 1.2x 14.5x
EV/FCF 65.8x -50.7x –
EV/Operating cash flow 38.4x 90.7x -76.4x
PEG (3Y EPS CAGR) 1.70 -9.16 -1.22

Growth

14 metrics
MetricNEOGVREXBFLY
Revenue growth (1Y) -0.3% 5.3% 39.4%
Revenue CAGR (3Y) -1.3% -1.2% 21.7%
Gross profit growth (1Y) 1.8% 6.1% 126.4%
Gross profit CAGR (3Y) -3.1% 1.2% 30.5%
Operating income growth (1Y) 99.3% 297.8% 33.5%
Operating income CAGR (3Y) -29.0% -2.3% 26.9%
Net income growth (1Y) 94.6% 116.7% 32.8%
Net income CAGR (3Y) -28.3% -9.2% 24.2%
EPS growth (1Y) 94.6% 116.1% 35.4%
EPS CAGR (3Y) -28.0% -3.8% 30.0%
Operating cash flow growth (1Y) -1.9% -81.1% 5.8%
Operating cash flow CAGR (3Y) 2.9% -47.6% 41.1%
Free cash flow growth (1Y) 1,631% -155.5% –
Free cash flow CAGR (3Y) 126.1% -33.5% –

Profitability

14 metrics
MetricNEOGVREXBFLY
Gross margin 47.4% 34.3% –
EBITDA margin 12.5% 11.7% –
Operating margin -0.8% 8.3% –
Pretax margin -7.7% 3.2% –
Net margin -6.3% 2.6% –
FCF margin 5.6% -2.3% –
Operating cash flow margin 9.6% 1.3% -19.0%
Return on equity -2.7% 4.5% –
Return on assets -1.7% 2.1% –
Return on invested capital -0.2% 6.9% –
Return on capital employed -0.2% 8.0% –
Asset turnover 0.3x 0.8x 0.4x
Cash conversion (OCF / net income) -1.5x 0.5x 0.4x
Stock comp / revenue 1.3% 1.7% 20.8%

Financial Health

11 metrics
MetricNEOGVREXBFLY
Debt / assets 23.4% 31.6% –
Debt / equity 0.4x 0.7x –
Net debt / EBITDA 5.4x 2.5x –
Debt / FCF 15.5x -17.2x –
Liabilities / assets 36.8% 53.6% 36.0%
Equity / assets 63.2% 46.4% 64.0%
Interest coverage – 1.9x –
Current ratio 3.9x 3.4x –
Quick ratio 2.1x 1.3x –
Cash ratio 1.2x 0.5x –
Altman Z-score 1.50 2.29 –

Shareholder Returns

7 metrics
MetricNEOGVREXBFLY
Dividend yield – – –
Net buyback yield -0.1% -0.4% –
Shareholder yield -0.1% -0.4% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusNEOGVREXBFLY
Forward P/E 38.3xFY2026 21.2xFY2026 –
EPS, next fiscal year $0.32FY2026 $0.87FY2026 $-0.10FY2026
EPS growth, next FY 0.0%FY2026 -3.3%FY2026 –
EPS growth, the year after +31.3% +14.9% –
Revenue, next fiscal year $847.28MFY2026 $829.68MFY2026 $114.50MFY2026
Revenue growth, next FY -2.7%FY2026 -1.8%FY2026 +17.3%FY2026
Revenue growth, the year after -1.5% +2.3% +26.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersNEOGVREXBFLY
Held by institutions 100.0% 95.2% 59.9%
Institutions holding 315 187 246
Change in shares held, QoQ +1.6% -2.7% +13.9%
Institutions buying 151 99 143
Institutions selling 106 58 59
Buyers to sellers 1.42 1.71 2.42

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

NEOGVREXBFLY
NEOG 1.00 0.25 0.24
VREX 0.25 1.00 0.20
BFLY 0.24 0.20 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, NEOG, VREX and BFLY?

Neogen (NEOG) is the largest by market capitalisation: Neogen (NEOG) $2.56B, Varex Imaging (VREX) $775.90M, Butterfly Network (BFLY) $1.67B.

Which company is growing faster?

Butterfly Network (BFLY) grew revenue fastest over the trailing twelve months: Neogen (NEOG) -0.3%, Varex Imaging (VREX) +5.3%, Butterfly Network (BFLY) +39.4%.

Which company is more profitable?

Varex Imaging (VREX) has the highest net margin (Neogen (NEOG) -6.3%, Varex Imaging (VREX) 2.6%). On return on invested capital, Varex Imaging (VREX) leads (Neogen (NEOG) -0.2%, Varex Imaging (VREX) 6.9%).

Which stock has performed better?

Over the past year Butterfly Network (BFLY) returned the most: Neogen (NEOG) +96.8%, Varex Imaging (VREX) +53.4%, Butterfly Network (BFLY) +249.3%. Over five years, Butterfly Network (BFLY) compounded fastest (Neogen (NEOG) -22.0%/yr, Varex Imaging (VREX) -7.2%/yr, Butterfly Network (BFLY) -6.2%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Neogen (NEOG) has been the steadiest (Neogen (NEOG) 55.7%, Varex Imaging (VREX) 57.2%, Butterfly Network (BFLY) 115.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, NEOG, VREX and BFLY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Varex Imaging (VREX) leads on 4. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.